我们认为，后附汇总表所载资料与我们审计康拓医疗公司 2024 年度财务报表时所复核 的会计资料和经审计的财务报表的相关内容，在所有重大方面没有发现不一致。 为了更好地理解康拓医疗公司 2024 年度非经营性资金占用及其他关联资金往来情况， 后附汇总表应当与已审的财务报表一并阅读。 关于西安康拓医疗技术股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 委托单位：西安康拓医疗技术股份有限公司 审计单位：中审众环会计师事务所（特殊普通合伙） 联系电话：029-68318314 1、 专项审计报告 2、 附表 关于西安康拓医疗技术股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 众环专字（2025）0800010 号 西安康拓医疗技术股份有限公司全体股东： 我们接受委托，在审计了西安康拓医疗技术股份有限公司（以下简称"康拓医疗公司"） 2024 年 12 月 31 日合并及母公司的资产负债表，2024 年度合并及母公司的利润表、合并及 母公司的现金流量表和合并及母公司的股东权益变动表以及财务报表附注的基础上，对后 附的《上市公司 2024 年度非经营性资金占 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2025-013 西安康拓医疗技术股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 关于召开 2024 年年度股东大会的通知 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 召开日期时间：2025 年 4 月 18 日 14 点 00 分 股东大会召开日期：2025年4月18日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 召开地点： ...

证券代码：688314 证券简称：康拓医疗 公告编号：2025-005 西安康拓医疗技术股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 西安康拓医疗技术股份有限公司(以下简称"公司")第二届监事会第十一次 会议于 2025 年 3 月 26 日在公司会议室以现场表决的方式召开，会议通知已于 2025 年 3 月 14 日通过邮件的方式送达全体监事。本次会议由监事会主席帖凯先 生主持，会议应出席监事 3 人，实际出席监事 3 人。会议召开符合《中华人民共 和国公司法》（以下简称"《公司法》"）《上海证券交易所科创板股票上市规 则》等有关法律、行政法规、部门规章、规范性文件和《西安康拓医疗技术股份 有限公司章程》（以下简称"《公司章程》"）的规定，会议召开合法、有效。 二、监事会会议审议情况 经与会监事审议表决，形成会议决议如下: （一）审议通过《关于公司 2024 年度监事会工作报告的议案》 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票，回避 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2025-004 西安康拓医疗技术股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 西安康拓医疗技术股份有限公司(以下简称"公司")第二届董事会第十五 次会议于2025年3月26日在公司会议室以现场及通讯表决的方式召开，会议通知 已于2025年3月14日通过邮件的方式送达全体董事。本次会议由董事长胡立人先 生主持，会议应出席董事9人，实际出席董事9人，部分监事、高级管理人员列 席。会议召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 《上海证券交易所科创板股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《西安康拓医疗技术股份有限公司章程》（以下简称"《公司章 程》"）的规定，会议召开合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司2024年年度报告及摘要的议案》 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票，回避票 0 票。 公司 2024 年年度报告的 ...

本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 证券代码：688314 证券简称：康拓医疗 告编号：2025-006 西安康拓医疗技术股份有限公司 关于 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例，每股转增比例：每 10 股派发现金红利 1.8 元（含 税）。 公司拟向全体股东每 10 股派发现金红利 1.8 元（含税）。截至 2024 年 12 月 31 日，公司总股本 81,239,172 股，以此计算合计拟派发现金红利 14,623,050.96 元（含税）。如在本公告披露之日起至实施权益分派股权登记日 期间，因可转债转股/回购股份/股权激励授予股份回购注销/重大资产重组股份 回购注销等致使公司总股本发生变动的，公司拟维持分配总额不变，相应调整 每股分配比例。如后续总股本发生变化，将另行公告具体调整情况。本次利润 分配方案尚需提交公司 2024 年年度股东大会审议。 公司于 2024 年 11 月 19 日 ...

Financial Performance - The company's operating revenue for 2024 reached ¥321,945,239.35, representing a year-on-year increase of 17.06% compared to ¥275,025,921.27 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥88,399,138.29, up 17.07% from ¥75,510,975.16 in 2023[18]. - The net cash flow from operating activities increased by 64.57% to ¥140,254,554.88 in 2024, compared to ¥85,224,591.84 in 2023[18]. - The company's total assets as of the end of 2024 were ¥747,222,862.91, a 10.57% increase from ¥675,787,403.12 at the end of 2023[19]. - The net assets attributable to shareholders increased by 8.24% to ¥635,577,490.21 at the end of 2024, compared to ¥587,184,063.37 at the end of 2023[19]. - Basic earnings per share for 2024 were ¥1.09, reflecting a 17.2% increase from ¥0.93 in 2023[20]. - The company reported a significant increase in other income by 153.69% to ¥13,329,126.18, mainly from subsidies for innovative medical devices[88]. - The gross margin for the medical device manufacturing sector was 80.23%, a decrease of 1.54 percentage points year-on-year[90]. - Domestic revenue accounted for 92.33% of total revenue, with a growth of 18.47% to ¥287,798,645.58[91]. - The company reported a net profit of 74.86 million yuan after deducting non-recurring gains and losses, reflecting a 9.52% year-on-year growth[29]. Research and Development - Research and development expenses accounted for 9.19% of operating revenue in 2024, up from 6.41% in 2023, indicating a focus on innovation[20]. - The company achieved a total R&D investment of ¥29,575,848.07, representing a 67.69% increase compared to the previous year[65]. - The proportion of R&D investment to operating income increased by 2.78 percentage points to 9.19%[65]. - The company obtained 4 new invention patents during the reporting period, focusing on PEEK bone plate technology and neurosurgery fixation techniques[63]. - The company has a cumulative total of 20 invention patent applications, with 14 granted[63]. - The company has successfully developed a unique micro-sphere production process that enhances the long-term efficacy of injectable fillers[70]. - The company has established multiple R&D platforms, including a 3D printing technology platform, to drive innovation and product development[177]. - The company emphasizes clinical demand-driven R&D, focusing on upgrading existing products and developing new technologies to address clinical pain points[54]. Corporate Governance - The company has a standard unqualified audit report from Zhongzheng Zhonghuan Accounting Firm[3]. - The company does not have any special arrangements for corporate governance[5]. - The company has improved its governance structure, optimizing its dividend policy and enhancing the role of independent directors to protect minority shareholders' rights[131]. - The company has established a specialized meeting mechanism for independent directors to strengthen their supervisory functions[131]. - The company has independent directors serving in various capacities, including positions at Guangdong Jinko Electronics Co., Ltd. and Xi'an Tianli Metal Composite Materials Co., Ltd.[138]. - The company's board of directors and supervisory board have confirmed the remuneration for directors, supervisors, and senior management for the 2023 fiscal year and proposed the remuneration plan for 2024[140]. - The company has established a comprehensive internal control system, which was independently audited and received a standard unqualified opinion for the 2024 internal control audit report[163]. Market Expansion and Product Development - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[18]. - The company has expanded its international business, covering over 30 countries, and is localizing PEEK bone plate production in the U.S. to enhance operational efficiency[37]. - The company is actively seeking partnerships with international leaders to introduce scarce bio-absorbable materials for craniofacial applications[33]. - The company is committed to enhancing the market influence of its craniofacial repair products through diversified promotion strategies, including online and offline marketing[128]. - The company aims to enhance its market share in the domestic neurosurgery segment while actively expanding its international business[125]. - By 2025, the company plans to increase the market penetration of PEEK material products and promote innovative products like the 4D bioactive plate and full PEEK cranial repair solutions[126]. Environmental and Social Responsibility - The company is committed to ESG principles, integrating sustainable development strategies into daily operations[165]. - The company donated a total of RMB 6 million for charity and poverty alleviation efforts during the reporting period[180]. - The company provided RMB 5 million in poverty alleviation donations to the local government, demonstrating its commitment to social responsibility[181]. - The company has implemented a waste management system for both general and hazardous waste, ensuring proper classification and disposal[173]. - The company emphasizes environmental protection and has established an emergency response mechanism for environmental pollution incidents[174]. Risks and Challenges - The company reported no significant risks affecting its operations during the reporting period[5]. - The company faces risks related to new product development and registration failures, which could adversely affect its long-term core competitiveness[78]. - The company is exposed to risks from centralized procurement policies, which may lead to price declines and impact profitability[80]. Employee Management and Development - The company has a structured training program aimed at enhancing employee skills and promoting career development[152][153]. - The number of R&D personnel increased to 53, representing 17.04% of the total workforce, up from 46 and 16.67% in the previous period[72]. - The average salary of R&D personnel is RMB 20.37 million, reflecting a slight increase from RMB 20.03 million in the previous period[72]. - The company has implemented a "key position personnel capability training plan" to support the growth of critical staff[129]. Shareholder and Dividend Policy - The company plans to distribute a cash dividend of 1.8 RMB per 10 shares, totaling approximately 14,623,050.96 RMB (including tax) based on a total share capital of 81,239,172 shares[4]. - The company has established a clear cash dividend policy to protect the rights of minority shareholders[155]. - The total cash dividend planned for 2024, including the first three quarters and the annual distribution, is RMB 29,246,101.92, representing 33.08% of the net profit attributable to shareholders[158]. - The cumulative cash dividend amount over the last three fiscal years (including tax) was CNY 85,417,186.56, representing a cash dividend ratio of 108.46% of the average annual net profit[159].

Financial Performance - The company reported a basic earnings per share of 1.09 yuan for 2024, an increase of 17.2% compared to 0.93 yuan in 2023 [1] - The net profit for 2024 was 0.88 billion yuan, reflecting a 15.79% increase from 0.76 billion yuan in 2023 [1] - The operating revenue reached 3.22 billion yuan, up 17.09% from 2.75 billion yuan in the previous year [1] - The return on equity (ROE) improved to 14.37% in 2024, compared to 13.46% in 2023, marking a 6.76% increase [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 58.03 million shares, accounting for 71.44% of the circulating shares, with a change of 501,700 shares from the previous period [2] - The largest shareholder, Hu Liren, holds 39.55 million shares, representing 48.68% of the total share capital, with no change [2] - New entrants among the top shareholders include Industrial Bank Co., Ltd. - Fortune Xinyuan Preferred 12-Month Holding Mixed Securities Investment Fund, holding 1.61 million shares [2] Dividend Distribution - No specific information regarding the dividend distribution plan was provided in the documents [3]

Investment Rating - The investment rating for 康拓医疗 (688314.SH) is "Buy" (maintained) [1] Core Views - The company is expected to achieve steady revenue and profit growth in 2024, with a projected revenue of 322 million yuan, representing a year-over-year increase of 17.06%. The net profit attributable to the parent company is expected to be 89 million yuan, up 17.30% year-over-year [4][6] - The penetration rate of PEEK materials in the neurosurgery segment is anticipated to continue increasing, driven by the implementation of inter-provincial alliances for neurosurgery procurement in Henan province [4][6] - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 89 million, 115 million, and 150 million yuan respectively, with corresponding EPS of 1.09, 1.42, and 1.85 yuan [4][6] Financial Summary - Revenue for 2024 is projected at 322 million yuan, with a year-over-year growth of 17.0%. The net profit for the same year is expected to be 89 million yuan, reflecting a growth of 17.3% [6][12] - The gross margin is projected to be 79.7% in 2024, with a net margin of 27.5% [6][12] - The P/E ratios for 2024, 2025, and 2026 are expected to be 30.7, 23.7, and 18.1 respectively [6][12] Product and Market Insights - PEEK neurosurgery products remain the main growth driver, with significant revenue growth expected from PEEK chest fixation devices [4] - The company has a comprehensive product line for cranial repair and fixation surgeries, with PEEK materials showing substantial growth potential in market penetration [4][6] - The company is expanding its overseas operations, including local production of PEEK plates in the U.S. to enhance market responsiveness and operational efficiency [4][6]

医药生物/医疗器械 康拓医疗（688314.SH） 2024 年收入利润稳健增长，PEEK 渗透率持续提升 2025 年 02 月 28 日 投资评级：买入（维持） 数据来源：聚源 -40% -20% 0% 20% 40% 60% 2024-02 2024-06 2024-10 康拓医疗 沪深300 | 日期 | 2025/2/27 | | --- | --- | | 当前股价(元) | 33.51 | | 一年最高最低(元) | 35.00/17.15 | | 总市值(亿元) | 27.22 | | 流通市值(亿元) | 27.22 | | 总股本(亿股) | 0.81 | | 流通股本(亿股) | 0.81 | | 近 3 个月换手率(%) | 52.34 | 相关研究报告 股价走势图 《2024H1 收入利润超预期，PEEK 骨 板渗透率提升中—公司信息更新报 告》-2024.8.14 《2023 年收入再创新高，PEEK 产品 成长力依旧可期—公司信息更新报 告》-2024.4.19 余汝意（分析师） 司乐致（分析师） 证书编号：S0790523070002 silezhi@kysec.cn 证书编号 ...

Financial Performance - In 2024, the company achieved total operating revenue of RMB 32,194.52 million, an increase of 17.06% compared to the previous year[6] - The net profit attributable to the parent company was RMB 8,857.08 million, reflecting a growth of 17.30% year-on-year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 7,503.25 million, up by 9.77% from the previous year[6] - Earnings per share rose to RMB 1.09, an increase of 17.20% from RMB 0.93 in the previous year[4] - The weighted average return on net assets improved to 14.57%, an increase of 1.11 percentage points from the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were RMB 74,706.60 million, a growth of 10.55% from the beginning of the period[6] - The equity attributable to the parent company increased to RMB 63,575.27 million, representing an 8.27% increase compared to the beginning of the period[6] Revenue Growth - The revenue from PEEK material neurosurgical products reached RMB 20,595.87 million, marking a 23.00% increase year-on-year[6] - The company accelerated the admission of neurosurgical products and expanded coverage in lower-tier markets, contributing to the net profit growth[7] Audit and Reporting - The company emphasizes that the financial data is preliminary and subject to final audit in the annual report[8]